Product Images Losartan Potassium

The text shows the results of a study comparing the effectiveness of two medications, Atenolol and Losartan Potassium, in reducing the risk of a primary endpoint. The study lasted for 66 months and results show that the adjusted risk reduction was 13% with a p-value of 0.021. There is no additional information available about the study or the primary endpoint being evaluated.*

This text shows the comparison between Atenolol and Losartan Potassium in terms of their adjusted risk reduction percentage for fatal/non-fatal stroke. The data seems to be represented in a graph form, with the study months displayed at the bottom axis and the percentage of patients at the vertical axis.*

This is a figure with demographic subgroups showing primary endpoint events for a study that measured the efficacy of two drugs. The primary composite stroke (fatal/non-fatal) was measured for Menolol and Atenolol. The figure includes different demographic subgroups such as age (B5years, >= 65years), gender, and ethnicity, with sample size proportional symbols. The results of the study were adjusted for the baseline Framingham risk score and level of electrocardiographic left ventricular hypertrophy.*

This appears to be a fragment of a statistical analysis report. It states the percentage of risk reduction for patients with an event, along with a p-value of 0.022. There is no context or explanation provided, so it is not possible to determine the specifics of the analysis.*

This is a table that shows the pharmacokinetic parameters in hypertensive adults and children aged 6-16 following multiple dosing. For adults given 50 mg once daily for 7 days (N=12), and for age 6-16 given 0.7 mg/kg once daily for 7 days (N=25), the table displays data on the parent active metabolite, AUCoxs, Chuax, Tia, Torae, and CLgzy. The data includes mean, harmonic mean, standard deviation, and median values.*

The text appears to be a table presenting the incidence of primary endpoint events with Losartan and Potassium Atenolol. The table contains rates and percentages for each medication in relation to the primary composite endpoint and its components, such as stroke, myocardial infarction, and cardiovascular mortality. The table includes the p-value and confidence interval for the reduction of the primary endpoint. Additionally, the table has notes specifying the follow-up period and adjustment for risk factors.*

The table shows the incidence and risk reduction of primary endpoint events for losartan and placebo. The primary composite endpoint has an incidence of 43.5% for losartan and 47.1% for placebo with a p-value of 0.022. The doubling of serum creatinine, end-stage renal disease (ESRD), and death occurring as the first event have an incidence of 216% for losartan and 260% for placebo. The overall incidence for doubling of serum creatinine, ESRD, and death has an incidence of 19.6% for losartan and 28.6% for placebo with a p-value of 0.002. The incidence and risk reduction for death are 210% and 203%, respectively.*

Table 5 provides the results of a study evaluating the efficacy outcomes within demographic subgroups. The primary composite endpoint is presented along with the number of events, event rates, and hazard ratios for Losartan and Placebo. The subgroups evaluated include age, race, and ethnicity. The results suggest that Losartan is effective in reducing the primary composite endpoint in all subgroups evaluated.*